Evidence map›Paper›PMID 16954231›Full record

ArticleJournal of clinical microbiology2006

Enhanced patient serum immunoreactivity to recombinant Mycobacterium tuberculosis CFP32 produced in the yeast Pichia pastoris compared to Escherichia coli and its potential for serodiagnosis of tuberculosis.

Chaouki Benabdesselem, Dahmani M Fathallah, Richard C Huard, Hongxia Zhu, Mohamed Ali Jarboui, Koussay Dellagi, John L Ho, Ridha M Barbouche

Abstract readComparative StudyEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Immunogenicity of heparin-binding hemagglutinin expressed byIranian journal of basic medical sciences · 2018
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chaouki BenabdesselemLaboratory of Immunopathology, Vaccinology, and Molecular Genetics, Institut Pasteur de Tunis, Tunis, Tunisia.
Dahmani M Fathallah
Richard C Huard
Hongxia Zhu
Mohamed Ali Jarboui
Koussay Dellagi
John L Ho
Ridha M Barbouche

Funding

TUBERCULOSIS INTERNATIONAL TRAINING AND RESEARCH PROGRAMD43TW000018 · FIC · WEILL MEDICAL COLL OF CORNELL UNIV · PI JOHNSON, WARREN DOUGLAS · 1988 to 2012
$16.1M
Antigen Capture Assays for Rapid Tuberculosis DiagnosisR21AI062332 · NIAID · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI HO, JOHN LAP · 2004 to 2005
$461k
FIC NIH HHS 3 D43 TW000018FIC NIH HHS D43 TW000018NIAID NIH HHS R21 AI062332
6 · The paper itself

Abstract

CFP32 is a Mycobacterium tuberculosis complex-restricted secreted protein that was previously reported to be present in a majority of sputum samples from patients with active tuberculosis (TB) and to stimulate serum antibody production. CFP32 (originally annotated as Rv0577 and also known as TB27.3) was therefore considered a good candidate target antigen for the rapid serodiagnosis of TB. However, the maximal sensitivity of CFP32 serorecognition may have been limited in earlier studies because recombinant CFP32 (rCFP32) produced in Escherichia coli was used as the test antibody-capture antigen, a potential shortcoming stemming from differences in bacterial protein posttranslational modifications. To further investigate the serodiagnostic potential of rCFP32 synthesized in different heterologous hosts, we expressed rCFP32 in the yeast Pichia pastoris. Compared to E. coli rCFP32, yeast rCFP32 showed a higher capacity to capture polyclonal antisera in Western blot studies. Likewise, yeast rCFP32 was significantly better recognized by the sera from TB patients and healthy Mycobacterium bovis bacillus Calmette-Guérin (BCG)-vaccinated individuals, by enzyme-linked immunosorbent assay (ELISA), than E. coli rCFP32. In subsequent testing, the yeast rCFP32-based antibody-capture ELISA had a sensitivity of 85% and a specificity of 98% for the discrimination of active TB cases (n = 40) from BCG vaccinees (n = 39). The sensitivity was surprisingly high for a single-antigen TB serodiagnostic test compared to tests using E. coli-expressed antigens. Overall, the trans-production of rCFP32 in P. pastoris significantly improved the serologic detection of CFP32-specific antibodies in patient sera, thereby offering a new, possibly better, modality for producing antigens of diagnostic potential for use in the development of immunoassays for both TB and other infectious diseases.

Indexed as

Antibodies, BacterialAntigens, BacterialBacterial ProteinsEscherichia coliHumansMycobacterium tuberculosisPichiaRecombinant ProteinsSensitivity and SpecificitySerologic TestsTuberculosis, PulmonaryAntibodies, BacterialAntigens, BacterialBacterial ProteinsCfp32 protein, Mycobacterium tuberculosisRecombinant Proteins

Identifiers

PMID16954231
PMCPMC1594712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.